Citations

Clear

6 citation(s) found for "Smith, Peter".

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
Spikes, Leslie , Eggert, Michael, Johri, Shilpa , Joly, Joanna M., Mehta, J.P. , Palevsky, Harold I. , Ramani, Gautam , Restrepo‐Jaramillo, Ricardo, Sahay, Sandeep , Shah, Trushil , Miceli, Melissa, Smith, Peter , Shapiro, Shelley, Spikes, Leslie A , Sahay, Sandeep , Bajwa, Abubakr A. , Burger, Charles D. , Desai, Sapna V., El‐Kersh, Karim , Fisher, Micah R., Deng, Chunqin

Mayo Clinic

Pulmonary Circulation | March 23, 2022 | Volume: 12 | Issue: 2 | Pages: No page available

10.1002/pul2.12063 | PMID 35514770 Get It

AbstractInhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and safety of nebulized inhaled treprostinil, but it requires a time investment for nebulizer preparation, maintenance, and treatment. A small, portable treprostinil dry powder inhaler has been developed for the treatment of PAH. The primary objective of this study was to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in patients currently treated with treprostinil inhalation solution. Fifty‐one patients on a stable dose of treprostinil inhalation solution enrolled and transitioned to TreT at a corresponding dose. Six‐minute walk distance (6MWD), device preference and satisfaction (Preference Questionnaire for Inhaled Treprostinil Devices [PQ‐ITD]), PAH Symptoms and Impact (PAH‐SYMPACT®) questionnaire, and systemic exposure and pharmacokinetics for up to 5 h were assessed at baseline for treprostinil inhalation solution and at Week 3 for TreT. Adverse events (AEs) were consistent with studies of inhaled treprostinil in patients with PAH, and there were no study drug‐related serious AEs. Statistically significant improvements occurred in 6MWD, PQ‐ITD, and PAH‐SYMPACT. Forty‐nine patients completed the 3‐week treatment phase and all elected to participate in an optional extension phase. These results demonstrate that, in patients with PAH, transition from treprostinil inhalation solution to TreT is safe, well‐tolerated, and accompanied by statistically significant improvements in key clinical assessments and patient‐reported outcomes with comparable systemic exposure between the two formulations at evaluated doses (trial registration: clinicaltrials.gov identifier: NCT03950739).
Peripheral nerve repair throughout the body with processed nerve allografts: Results from a large multicenter study
Safa, Bauback , Jain, Sonu A. , Desai, Mihir J., Greenberg, Jeffrey A., Niacaris, Timothy, Nydick, Jason A. , Leversedge, Fraser J. , Megee, David M., Zoldos, Jozef, Rinker, Brian, McKee, Desirae , MacKay, Brendan J. , Ingari, John V. , Nesti, Leon J. , Cho, Mickey, Valerio, Ian L. , Kao, Dennis S. , El‐Sheikh, Yasser, Weber, Renata V., Shores, Jaimie T. , Styron, Joseph F. , Thayer, Wesley P. , Przylecki, Wojciech, Hoyen, Harry A. , Buncke, Gregory M.

Mayo Clinic

Microsurgery | February 26, 2020 | Volume: 40 | Issue: 5 | Pages: 527-537

10.1002/micr.30574 | PMID 32101338 Get It

AbstractBackgroundPeripheral nerve damage resulting in pain, loss of sensation, or motor function may necessitate a reconstruction with a bridging material. The RANGER® Registry was designed to evaluate outcomes following nerve repair with processed nerve allograft (Avance® Nerve Graft; Axogen; Alachua, FL). Here we report on the results from the largest peripheral nerve registry to‐date.MethodsThis multicenter IRB‐approved registry study collected data from patients repaired with processed nerve allograft (PNA). Sites followed their own standard of care for patient treatment and follow‐up. Data were assessed for meaningful recovery, defined as ≥S3/M3 to remain consistent with previously published results, and comparisons were made to reference literature.ResultsThe study included 385 subjects and 624 nerve repairs. Overall, 82% meaningful recovery (MR) was achieved across sensory, mixed, and motor nerve repairs up to gaps of 70 mm. No related adverse events were reported. There were no significant differences in MR across the nerve type, age, time‐to‐repair, and smoking status subgroups in the upper extremity (p > .05). Significant differences were noted by the mechanism of injury subgroups between complex injures (74%) as compared to lacerations (85%) or neuroma resections (94%) (p = .03) and by gap length between the <15 mm and 50–70 mm gap subgroups, 91 and 69% MR, respectively (p = .01). Results were comparable to historical literature for nerve autograft and exceed that of conduit.ConclusionsThese findings provide clinical evidence to support the continued use of PNA up to 70 mm in sensory, mixed and motor nerve repair throughout the body and across a broad patient population.
Non-Lethal Type VIII Osteogenesis Imperfecta Has Elevated Bone Matrix Mineralization
Fratzl‐Zelman, Nadja , Barnes, Aileen M. , Weis, MaryAnn , Carter, Erin , Hefferan, Theresa E., Perino, Giorgio , Chang, Weizhong , Smith, Peter A. , Roschger, Paul, Klaushofer, Klaus, Glorieux, Francis H. , Eyre, David R. , Raggio, Cathleen , Rauch, Frank , Marini, Joan C. , Carter, Erin M.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 6, 2016 | Volume: 101 | Issue: 9 | Pages: 3516-3525

10.1210/jc.2016-1334 | PMID 27383115 Get It

Abstract Context: Type VIII osteogenesis imperfecta (OI; OMIM 601915) is a recessive form of lethal or severe OI caused by null mutations in P3H1, which encodes prolyl 3-hydroxylase 1. Objectives: Clinical and bone material description of non-lethal type VIII OI. Design: Natural history study of type VIII OI. Setting: Pediatric academic research centers. Patients: Five patients with non-lethal type VIII OI, and one patient with lethal type VIII OI. Interventions: None. Main Outcome Measures: Clinical examinations included bone mineral density, radiographs, and serum and urinary metabolites. Bone biopsy samples were analyzed for histomorphometry and bone mineral density distribution by quantitative backscattered electron imaging microscopy. Collagen biochemistry was examined by mass spectrometry, and collagen fibrils were examined by transmission electron microscopy. Results: Type VIII OI patients have extreme growth deficiency, an L1–L4 areal bone mineral density Z-score of −5 to −6, and normal bone formation markers. Collagen from bone and skin tissue and cultured osteoblasts and fibroblasts have nearly absent 3-hydroxylation (1–4%). Collagen fibrils showed abnormal diameters and irregular borders. Bone histomorphometry revealed decreased cortical width and very thin trabeculae with patches of increased osteoid, although the overall osteoid surface was normal. Quantitative backscattered electron imaging showed increased matrix mineralization of cortical and trabecular bone, typical of other OI types. However, the proportion of bone with low mineralization was increased in type VIII OI bone, compared to type VII OI. Conclusions: P3H1 is the unique enzyme responsible for collagen 3-hydroxylation in skin and bone. Bone from non-lethal type VIII OI children is similar to type VII, especially bone matrix hypermineralization, but it has distinctive features including extremely thin trabeculae, focal osteoid accumulation, and an increased proportion of low mineralized bone.
The Multiligament Quality of Life Questionnaire
Chahal, Jaskarndip , Whelan, Daniel B. , Jaglal, Susan , Smith, Peter , MacDonald, Peter B. , Levy, Bruce A. , Davis, Aileen M. , Davis, Aileen

Mayo Clinic

The American Journal of Sports Medicine | October 6, 2014 | Volume: 42 | Issue: 12 | Pages: 2906-2916

10.1177/0363546514552629 | PMID 25288625 Get It

Background: Existing knee joint–specific outcome questionnaires lack content pertinent to patients with multiligament knee injuries. Purpose: To develop and test the reliability and validity of a novel disease-specific quality of life questionnaire for patients with multiligament knee injuries. Study Design: Cohort study (diagnosis); Level of evidence, 2. Methods: Participants in this study included patients with multiligament knee injuries and clinician experts. Inclusion criteria were (1) patients with multiligament knee injury (age, 18-60 years), (2) ≥6 months after injury, and (3) operative or nonoperative treatment. Exclusion criteria were (1) preexisting osteoarthritis or inflammatory arthritis and (2) intracerebral/spinal cord injury. In phase I of the study, 85 eligible patients were mailed a questionnaire composed of 132 items from 11 existing knee questionnaires. Items were rated with regard to importance and frequency on a 5-point Likert scale. Criteria for inclusion in the first draft of the Multiligament Quality of Life (MLQOL) questionnaire included mean importance rating ≥3.5 and frequency <30% for the response “never experienced.” In phase II, patient focus groups and expert interviews were conducted until no further new content was generated for the MLQOL, and in phase III, 99 eligible patients across 2 centers were mailed a preliminary MLQOL questionnaire along with the Tegner activity scale, Short Form (SF)–36, and anchor questions. Interitem and item-to-total correlations were used to perform item reduction to generate a final MLQOL instrument, which was tested for internal consistency (Cronbach alpha), test-retest reliability (interclass correlation coefficient [ICC]), and construct validity. Results: At the end of phase III, a final MLQOL instrument was developed that was composed of 4 domains (physical impairments [PI], emotional impairments [EI], activity limitations [AL], and societal involvement [SI]) with 52 items in total. The MLQOL had adequate content validity, as none of the domains had any floor or ceiling effects. The Cronbach alpha was .94 (PI), .93 (EI), .94 (AL), and .91 (SI); ICC values were .89 (PI), .86 (EI), .91 (AL), and .88 (SI). Seven of 8 a priori hypotheses were satisfied, indicating good construct validity. Conclusion: The MLQOL instrument is a novel disease-specific quality of life tool that has demonstrated excellent content validity, reliability, and construct validity.
A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting
Pifarré, Roque, Horrow, Jan C., Albus, Robert A., Spiess, Bruce D. , Rosengart, Todd K. , Murray, Jeffrey, Clark, Richard E. , Nadel, Andrea, Bonney, Sharon L., Kleinfield, Robert, Levy, Jerrold H. , Schaff, Hartzell V. , Smith, Peter K.

Mayo Clinic

Circulation | June 12, 2012 | Volume: 92 | Issue: 8 | Pages: 2236-2244

10.1161/01.cir.92.8.2236 | PMID 7554207 Get It

Background Aprotinin is a serine protease inhibitor that reduces blood loss and transfusion requirements when administered prophylactically to cardiac surgical patients. To examine the safety and dose-related efficacy of aprotinin, a prospective, multicenter, placebo-controlled trial was conducted in patients undergoing repeat coronary artery bypass graft (CABG) surgery. Methods and Results Two hundred eighty-seven patients were randomly assigned to receive either high-dose aprotinin, low-dose aprotinin, pump-prime-only aprotinin, or placebo. Drug efficacy was determined by the reduction in donor-blood transfusion up to postoperative day 12 and in postoperative thoracic-drainage volume. The percentage of patients requiring donor–red-blood-cell (RBC) transfusions in the high- and low-dose aprotinin groups was reduced compared with the pump-prime-only and placebo groups (high-dose aprotinin, 54%; low-dose aprotinin, 46%; pump-prime only, 72%; and placebo, 75%; overall P =.001). The number of units of donor RBCs transfused was significantly lower in the aprotinin-treated patients compared with placebo (high-dose aprotinin, 1.6±0.2 U; low-dose aprotinin, 1.6±0.3 U; pump-prime-only, 2.5±0.3 U; and placebo, 3.4±0.5 U; P =.0001). There was also a significant difference in total blood-product exposures among treatment groups (high-dose aprotinin, 2.2±0.4 U; low-dose aprotinin, 3.4±0.9 U; pump-prime-only, 5.1±0.9 U; placebo, 10.3±1.4 U). There were no differences among treatment groups for the incidence of perioperative myocardial infarction (MI). Conclusions This study demonstrates that high- and low-dose aprotinin significantly reduces the requirement for donor-blood transfusion in repeat CABG patients without increasing the risk for perioperative MI.